Genmab Announces Updates on Phase III Cancer Studies

Summary: Updates on Phase III studies with ofatumumab, zalutumumab and          
zanolimumab.                                                                    

Copenhagen, Denmark; May 29, 2008 - Genmab A/S (OMX: GEN) reports today that the
last patient to be included in the planned interim analysis (N=132 patients) in 
the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory
chronic lymphocytic leukemia (CLL) has now received the last scheduled          
treatment.                                                                      

In order to complete the database and allow for assessment of the responses by  
an independent committee, the final data will now be collected and analysed with
the results expected in early August 2008. Pending a positive outcome, a        
Biologics License application in this indication is expected to be filed before 
the end of 2008.                                                                

Ofatumumab is an investigational drug being developed to treat CLL, follicular  
non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and rheumatoid arthritis  
under a co-development and commercialization agreement between Genmab and       
GlaxoSmithKline.  It is not yet approved in any country.                        

Genmab also reported that to date, 132 patients have been dosed in the pivotal  
Phase III  study of zalutumumab (HuMax-EGFr(TM)) to treat head and neck cancer  
patients considered incurable with standard therapy.  As survival is the primary
endpoint of this study, a planned interim analysis will take place based on the 
survival data for patients participating in the study.  At present, the Company 
expects this analysis to occur in 2008, but the exact timing cannot be          
predicted.                                                                      

In addition, Genmab announced that based on current recruitment rates, despite  
broadening the inclusion criteria, the Company does not expect the data to be   
available this year from the ongoing pivotal Phase III study with zanolimumab   
(HuMax-CD4(R)) in refractory cutaneous T-cell lymphoma patients.                

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using cutting-edge  
antibody technology, Genmab's world class discovery, development and            
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders.  As Genmab advances towards a commercial future, we remain committed 
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options.  For more information on Genmab's products and           
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 24/2008                                              

###